BioStock publishes analysis of Idogen
Today, June 2 2017, BioStock has published an analysis of Idogen. The analysis is now available on BioStock’s, Idogen’s and Redeye’s respective websites (www.biostock.se, www.idogen.com, http://beta.redeye.se/transaction/idogen). On behalf of Idogen, Biostock has analyzed the company’s project portfolio and will continue to follow the company for one year.
Extract from BioStock’s analysis:
“BioStock has analyzed deal values and market caps to see how Idogen compares. Many of the deals have upfront
payments that exceed Idogen’s current market value. Interestingly, another cell therapy company with two preclinical projects is valued at roughly twice as Idogen’s current market cap. Perhaps this could be indicative of a future value when Idogen has established development within renal transplantation. Internationally, cell- and gene-based therapies belong to a space with high investment interest and BioStock believes that it’s just a matter of time until this trend reaches Scandinavian investors.”
Read the entire report here: http://www.biostock.se/2017/06/biostock-analys-idogen/
For additional information, please contact:
Lars Hedbys, CEO
Tel: 46 - 46 - 275 63 30
Idogen develops tolerogenic vaccines which re-program the immune system. The term "tolerogenic" refers to that the immune system will tolerate the selected molecule after treatment. It represents a new treatment method for severe diseases with a large medical need currently lacking cure – such as autoimmune diseases, organ rejection after transplantation and patients without treatment after developing antibodies against standard treatment.
The treatment method comprises cells from the patient's blood being reprogrammed to dendritic cells with the capacity to specifically counteract the adverse immune reaction, without affecting the other immune function. The first indication for the therapy will be patients with the bleeding disorder hemophilia A who have developed an immunological reaction against their necessary factor VIII replacement. The company's next therapeutic area will be a tolerogenic vaccine to counteract organ rejection in transplantation, primarily kidney transplantation. Idogen’s tolerogenic vaccine is expected to reduce the need for immunosuppressive therapy and increase transplant survival, and thereby reduce the risk of cancer and serious infections. Idogen was founded in 2008 based on a fundamental immunological discovery at Lund University. For more information, visit www.idogen.com